Zobrazeno 1 - 10
of 12
pro vyhledávání: '"S Guijarro Herrera"'
Autor:
N Márquez Pete, M Rodriguez Goicochea, R García Fumero, S Guijarro Herrera, E Gonzalez Del Valle, S Cano Domínguez
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance Early antifungal therapy for invasive pulmonary aspergillosis has been associated with better survival outcomes in immunocompromised patients. Isavuconazole, as well as caspofungin and liposomal amphotericin B (LAmB), is a r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46c7a852a359fae0f0d3354a5a96de9d
https://doi.org/10.1136/ejhpharm-2020-eahpconf.345
https://doi.org/10.1136/ejhpharm-2020-eahpconf.345
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Patients with multimorbidity are an especially complex population. Multimorbidity is associated with poorer health outcomes and significant polypharmacy. These make patients more vulnerable to drug-related problems, causing a higher number
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f726dd18e2f449c485e255bececb41e
https://doi.org/10.1136/ejhpharm-2019-eahpconf.534
https://doi.org/10.1136/ejhpharm-2019-eahpconf.534
Publikováno v:
Eur J Hosp Pharm
Background Lapatinib has been approved for the treatment of patients with advanced stage HER2-positive breast cancer (BC) patients with moderate survival rates. Purpose To analyse the prescription profile used and the demographic and clinical charact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ae30ab598771999ca2e3e67b423fdb0
https://europepmc.org/articles/PMC7535278/
https://europepmc.org/articles/PMC7535278/
Publikováno v:
Eur J Hosp Pharm
Background Vancomycin is a glycopeptide antibiotic active against gram-positive bacteria. Vancomycin pharmacokinetic parameters can vary widely among individuals. Drug monitoring is recommended if the duration of therapy is expected to be more than 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::828f57bf1e620e7eb0f08e6237d4cb23
https://europepmc.org/articles/PMC7535508/
https://europepmc.org/articles/PMC7535508/
Autor:
J Cabeza-Barrera, María Nuñez-Nuñez, R García Fumero, S Guijarro-Herrera, I Casas-Hidalgo, A Jiménez-Morales, L Martínez-Dueñas
Publikováno v:
Eur J Hosp Pharm
BACKGROUND: Mid-year supply problems of piperacillin/tazobactam (PT) led the Spanish Agency for Medicines and Health Products (AEMPS) to define a proposal to manage the approaching situation. AEMPS proffered some guidelines depending on the type of i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3657d5b7122a235dcaffef7aa8a3b862
https://europepmc.org/articles/PMC7535596/
https://europepmc.org/articles/PMC7535596/
Autor:
S Guijarro-Herrera, J Pasquau, R García-Fumero, M Sanchez-Argaiz, A Jiménez-Morales, S Sadyrbaeva
Publikováno v:
Eur J Hosp Pharm
Background The emergence of highly-resistant gram-negative bacteria, in particular acinetobacter baumanii pseudomonas aeruginosa, and carbapenem-resistant klebsiella species has been associated with high rates of morbidity and mortality. Therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d670d7fc2573a29da196a65096c601d
https://europepmc.org/articles/PMC7535293/
https://europepmc.org/articles/PMC7535293/
5PSQ-071 Efficacy and safety evaluation of trifluridine/tiparacil for metastatic colon cancer (mcrc)
Autor:
C Collado García, S Cano Domínguez, S Guijarro Herrera, F Artime Rodríguez-Hermida, A Jiménez Morales, R García Fumero, L Gutiérrez Zúñiga, CM Valencia Soto
Publikováno v:
Eur J Hosp Pharm
Background Trifluridine/tiparacile is the second oral treatment approved for patients with mCRC who have received fluoropyrimidine, oxaliplin- and irinotecan-based chemotherapy, an anti-VEGF biologic therapy and, if RAS wild-type, an anti-EGFR. Purpo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dc038c5eb5e45c3212b0f47f8338750
https://europepmc.org/articles/PMC7535737/
https://europepmc.org/articles/PMC7535737/
Autor:
M Carrasco Gomariz, N Martinez Casanova, M Lopez Martinez, A Cahue Urrutia, A Madrid Paredes, S Guijarro Herrera
Publikováno v:
Eur J Hosp Pharm
Background Proton pump inhibitors (PPIs) are often used inappropriately, without an indication, or for longer durations than recommended. Deprescribing is defined as the reduction, withdrawal or discontinuation of inappropriate medication. We aimed t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c1c5c8ee29039af717e7f855f516479
https://doi.org/10.1136/ejhpharm-2018-eahpconf.97
https://doi.org/10.1136/ejhpharm-2018-eahpconf.97
Autor:
S Guijarro Herrera, J Pastor Hurtado, CM Valencia Soto, JM Ruiz Gonzalez, Toscano Guzmán, E Román Márquez, S Cortes de Miguel, MV Villacañas Palomares
Publikováno v:
Eur J Hosp Pharm
Background In Spain, a therapeutic positioning report (TPR) for sacubitril valsartan indicates its use in adult patients for the treatment of symptomatic chronic heart failure and reduced ejection fraction (left ventricular ejection fraction (LVEF)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fda03c7ebf4ca0b8c6947f7e925dcf29
https://doi.org/10.1136/ejhpharm-2018-eahpconf.116
https://doi.org/10.1136/ejhpharm-2018-eahpconf.116
Publikováno v:
Eur J Hosp Pharm
Background Hidradenitis suppurativa (HS) is a chronic suppurative condition featuring inflammatory nodules, fistulas and scars. Its prevalence is estimated at 1% in Wwestern Europe. Adalimumab (Humira ® ) was approved in June 2015 as the first TNF b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1174eb1e865b4531b872ea00eed2393e
https://doi.org/10.1136/ejhpharm-2018-eahpconf.232
https://doi.org/10.1136/ejhpharm-2018-eahpconf.232